Crucell nabs $300M in Quinvaxem contracts

Dutch biotechnology firm Crucell won $300 million in contracts for it Quinvaxem pediatric vaccine, bringing total sales of the product to $800 million and pushing shares up by 3 percent. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.